Date: 2015-08-05
Type of information: Initiation of the trial
phase: 1
Announcement: initiation of the trial
Company: BMS (USA - NY) Ono Pharmaceutical (Japan)
Product: urelumab (BMS-663513)
Action
mechanism: monoclonal antibody. Urelumab (BMS-663513) is an agonist of the CD137 co-stimulatory receptor. This monoclonal antibody specifically binds to and activates CD137-expressing immune cells, stimulating an immune response, in particular a cytotoxic T cell response, against tumor cells. CD137 is a member of the tumor necrosis factor (TNF)/nerve growth factor (NGF) family of receptors and is expressed by activated T- and B-lymphocytes and monocytes. BMS and Ono Pharmaceutical jointly develop multiple immunotherapies as single agents and combination regimens to help address the unmet medical needs of patients with cancer in Japan, South Korea and Taiwan. This collaboration includes Opdivo® (nivolumab) and three additional early-stage clinical immuno-oncology assets from BMS: lirilumab (IPH2102 - developed with Innate Pharma), an antibody that blocks the KIR receptor on natural killer cells, urelumab, an agonist of the CD137 co-stimulatory receptor, and BMS-986016, a LAG3 immune checkpoint inhibitor.
Disease: malignant tumors
Therapeutic area: Cancer - Oncology
Country:
Trial
details: This phase 1 study will assess the safety and tolerability of urelumab (BMS-663513) in subjects with advanced and/or metastatic malignant tumors. (NCT02534506)
Latest
news: This phase 1 study will evaluate the safety, tolerability, pharmacokinetics and immunoregulatory activity of urelumab (BMS-663513) in subjects with advanced and/or metastatic malignant tumors.
